SAFETY DATA SHEET



Revision Date: 05.13.2020

Version 1.0

Page 1 of 7

1. IDENTIFICATION OF THE SUBSTANCE / MIXTURE AND THE COMPANY / UNDERTAKING

Product Identifier

Material Name:	Aminosyn Injection
Trade Name:	Not established
Synonyms:	None
Chemical Family:	Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against Intended Use: Pharmaceutical product

Details of the supplier of the Safety Data Sheet:

ICU Medical, Inc. 275 North Field Drive Lake Forest, IL 60045 (844) 654-7780

Emergency Telephone Number:

 Phone:
 1-(800) 241-4002, Option 6

 CHEMTREC (24 hours):
 1-800-424-9300

 email:
 MedInfo_US@icumed.onmicrosoft.com

2. HAZARD IDENTIFICATION

Classification of the Substance or Mixture

GHS – Classification	Not classified as hazardous
Label Elements Signal Word: Hazard Statements:	Not classified Not classified in accordance with international standards for workplace safety
Other Hazards:	No data available
Note:	This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending on the potential for exposure in your workplace.

Page **2** of **10**

Revision Date: 05.13.2020

Version 1.0

3. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredient	CAS Number	EU EINECS / ELINCS List	GHS Classification	%
L-Glutamic Acid	56-86-0	200-293-7	Not Listed	<1.5
Aspartic Acid	56-84-8	200-291-6	Not Listed	<1.5
Arginine	74-79-3	200-811-1	Not Listed	<2
Tyrosine	60-18-4	200-460-4	Not Listed	<1
Leucine	328-39-2	206-328-2	Not Listed	<2
Isoleucine	73-32-5	200-798-2	Not Listed	<1.5
Taurine	107-35-7	203-483-8	Not Listed	<0.2
Phenylalanine	63-91-2	200-568-1	Not Listed	<0.5
Histidine	71-00-1	200-745-3	Not Listed	<0.5
Methionine	63-68-3	200-562-9	Not Listed	<0.5
Serine	56-45-1	200-274-3	Not Listed	<1
Threonine	72-19-5	200-774-1	Not Listed	<1
Valine	72-18-4	200-773-6	Not Listed	<1
Proline	147-85-3	205-702-2	Not Listed	<1.5
Lysine Acetate	52315-76-1	257-845-5	Not Listed	<3
Alanine	56-41-7	200-273-8	Not Listed	<2
Glycine	56-40-6	200-272-2	Not Listed	<2
N-Acetyl-L-Tyrosine	537-55-3	208-671-3	Eye Damage (H318)	< 0.5
Tryptophan	73-22-3	200-795-6	Not Listed	<0.5
Water for Injection, USP	7732-18-5	231-791-2	Not Listed	>80

Additional Information: Ingredient indicated as hazardous has been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For full text of the CLP/GHS abbreviation mentioned in this section, see Section 16.

4. FIRST AID MEASURES

Description of First Aid Measures

- **Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. If irritation occurs or persists, obtain medical attention.
- **Skin Contact:** If irritation occurs, wash exposed area with soap and water, remove contaminated clothing and obtain medical assistance.
- **Ingestion:** Never give anything by mouth to an unconscious person. Wash mouth out with water and obtain medical attention immediately. Do not induce vomiting unless directed by medical personnel.
- Inhalation: Not an expected route of exposure.

Most Important Symptoms and Effects, Both Acute and Delayed

Revision Date: 05.13.2020

Symptoms and Effects No data available of **Exposure**:

Medical Conditions None Known Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO₂, dry chemical, foam, or water.

Special Hazards Arising from the Substance or Mixture Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire. May include oxides of carbon.

Fire / Explosion Hazards: Not applicable

Advice for Firefighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning /

Collecting: Contain the source of the spill, if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for

Large Spills: None

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment.

Page 3 of 10

Version 1.0

Page 4 of 10

Revision Date: 05.13.2020

Version 1.0

Colorless

Mixture

No data available

Conditions for safe storage, including any incompatibilities Storage Conditions: Store as directed by product packaging Incompatible Materials: None

Specific End Use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. **Personal Protective**

Refer to applicable national standards and regulations in the selection and use of personal Equipment: protective equipment (PPE).

Eye Protection: Wear safety glasses or goggles if eye contact is possible.

Hand Protection: Impervious gloves (e.g. nitrile, etc.) are recommended if skin contact with drug product is possible for bulk processing operations.

Skin Protection: Impervious protective clothing is recommended if skin contact with drug product is possible for bulk processing conditions.

Respiratory protection: None required under normal conditions of use.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Odor: Molecular Formula:	Liquid None Mixture	Color: Odor Threshold: Molecular Weight:
Solvent Solubility:	No data available	
Water Solubility:	No data available	
pH	5.0-6.5	
Melting/Freezing Point (°C):	No data available	
Partition Coefficient:	No data available	
Decomposition Temperature (°C):	No data available	
Evaporation Rate (gram/s):	No data available	
Vapor Pressure (kPa):	No data available	
Vapor Density (g/ml):	No data available	
Relative Density:	1.02 – 1.05 g/mL at 25 de	g. C
Viscosity:	1.03 – 1.62 cps at 25 deg.	С

Flammability:

Autoignition Temperature (Solid)(°C):	No data available
Flammability (solids):	No data available
Flash Point (Liquid)(°C):	No data available
Upper Explosive Limits (Liquid)(% by vol.)	No data available
Lower Explosive Limits (Liquid) (% by vol.)	No data available

SAFETY DATA SHEET

Material Name: Aminosyn Injection

Page 5 of 10

Revision Date: 05.13.2020

Version 1.0

10. STABILITY AND REACTIVITY

Reactivity: Chemical Stability: Possibility of Hazardous Reactions: Oxidizing Properties: Conditions to Avoid: Incompatible Materials: Hazardous Decomposition: Products: No data available Stable under normal conditions of use

No data available None No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects General Information:

The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

L Glutamic Acid Human intravenous TDLo50 117 mg/kg

Leucine Rat intraperitoneal LD50 5379 mg/kg

Isoleucine, USP Rat intraperitoneal LD50 6822 mg/kg

Tyrosine, USP Mouse intraperitoneal LD50 1450 mg/kg

Phenylalanine

Rat intraperitoneal LD50 5287 mg/kg Rabbit intraperitoneal LD50 1322 mg/kg

Taurine

Rat	Oral	LD50	5000 mg/kg
Rat	Intrav	enous LD50/	7000 mg/kg
Mouse	Oral	LD50	7000 mg/kg

Histidine

Rat	Oral LD50	15000 mg/kg
Rat	intravenous LD50	2000 mg/kg
Mous	e Oral LD50	15000mg/kg
Mous	e intravenous LD50	2000mg/kg

Methionine

Rat Oral LD50 36000 mg/kg

Revision Date: 05.13.2020

Threonine

Rat intraperitoneal LD50 3098 mg/kg Valine

Rat intraperitoneal LD50 5390 mg/kg

Orycine	Glycine	е
---------	---------	---

Giycin	e	
Rat	Oral LD50	7930 mg/kg
Rat	intravenous LD50	2600 mg/kg
Mouse	Oral LD50	4920 mg/kg
Mouse	intravenous LD50	2370mg/kg
		0· 0
Trypto	phan	
	Oral LD50	1300 mg/kg
riaman		rooo mg/ng
∆snart	ic Acid	
Rat	Oral TDLo	3000 mg/kg
nat		oooo mg/kg
Lycino	Acetate	
		"
Rat intr	avenous LD50	2850 mg/kg
Mouse	intravenous LD50	3200 mg/kg

Page 6 of 10

Version 1.0

12. ECOLOGICAL INFORMATION

Releases to the environment should be avoided. No acute toxicity to aquatic organisms is expected.
No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Revision Date: 05.13.2020

Page 7 of 10

Version 1.0

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental	Regulations/Legislation	Specific for the Substance or Mixture

L-Glutamic Acid CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory – United States TSCA Australia (AICS): EU EINECS / ELINCS List	Not Listed Not Listed Present Present 200-293-7
Aspartic Acid CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory – United States TSCA Australia (AICS): EU EINECS / ELINCS List	Not Listed Not Listed Present Present 200-291-6
Arginine CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory – United States TSCA Australia (AICS): EU EINECS / ELINCS List	Not Listed Not Listed Present Present 200-811-1
Tyrosine CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory – United States TSCA Australia (AICS): EU EINECS / ELINCS List	Not Listed Not Listed Present Present 200-460-4
Leucine CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory – United States TSCA Australia (AICS): EU EINECS / ELINCS List	Not Listed Not Listed Present Present 206-328-2
Isoleucine CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory – United States TSCA Australia (AICS): EU EINECS / ELINCS List	Not Listed Not Listed Present Present 627-025-5

Revision Date: 05.13.2020

Taurine	
CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory – United States TSCA Australia (AICS): EU EINECS / ELINCS List	Not Listed Not Listed Present Present 203-483-8
Phenylalanine CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory – United States TSCA Australia (AICS): EU EINECS / ELINCS List	Not Listed Not Listed Present Present 200-568-1
Histidine	
CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory – United States TSCA Australia (AICS): EU EINECS / ELINCS List	Not Listed Not Listed Present Present 200-745-3
Methionine	
CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory – United States TSCA Australia (AICS): EU EINECS / ELINCS List	Not Listed Not Listed Present Present 200-562-9
Serine	
CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory – United States TSCA Australia (AICS): EU EINECS / ELINCS List	Not Listed Not Listed Present Present 200-274-3
Threonine	
CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory – United States TSCA Australia (AICS): EU EINECS / ELINCS List	Not Listed Not Listed Present Present 200-774-1
Valine	
CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory – United States TSCA Australia (AICS): EU EINECS / ELINCS List	Not Listed Not Listed Present Present 200-773-6
Proline	
CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory – United States TSCA Australia (AICS): EU EINECS / ELINCS List	Not Listed Not Listed Present Present 205-702-2

Page 8 of 10

Version 1.0

Revision Date: 05.13.2020

Page 9 of 10

Version 1.0

Lysine Acetate CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory – United States TSCA Australia (AICS): EU EINECS / ELINCS List	Not Listed Not Listed Present Present 200-294-2
Alanine CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory – United States TSCA Australia (AICS): EU EINECS / ELINCS List	Not Listed Not Listed Present Present 206-126-4
Glycine CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory – United States TSCA Australia (AICS): EU EINECS / ELINCS List	Not Listed Not Listed Present Present 200-272-2
N-Acetyl-L-Tyrosine CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory – United States TSCA Australia (AICS): EU EINECS / ELINCS List	Not Listed Not Listed Present Present 208-671-3
Tryptophan CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory – United States TSCA Australia (AICS): EU EINECS / ELINCS List	
Water for Injection CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory – United States TSCA Australia (AICS): EU EINECS / ELINCS List	Not Listed Not Listed Present Present 231-791-2

Revision Date: 05.13.2020

Page 10 of 10

Version 1.0

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3 H318 – causes eye damage		
Data Sources:	Publicly available toxicity information.	
Reasons for Revision:	Company/Undertaking.	
Development date:	May 13, 2020	
Prepared by:	ICU Medical Environment, Health & Safety Department	

ICU Medical believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

END OF SAFETY DATA SHEET